Challenges in the Metabolomics-Based Biomarker Validation Pipeline
Abstract
:1. Introduction
1.1. Biomarkers
1.2. Metabolomics
2. Pre-Analytical Challenges
2.1. Patient Selection
2.2. Sample Collection and Storage
3. Analytical Validation
3.1. Analytical Validation Parameters
3.2. Metabolomics-Based Challenges
4. Kit Development
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Califf, R.M. Biomarker Definitions and Their Applications. Exp. Biol. Med. 2018, 243, 213–221. [Google Scholar] [CrossRef]
- Chen, X.-H.; Huang, S.; Kerr, D. Unit 4 • Chapter 17. In Biomarkers in Clinical Medicine; IARC Scientific Publications: Lyon, France, 2011. [Google Scholar]
- Food and Drug Administration; National Institutes of Health. BEST (Biomarkers, EndpointS, and Other Tools) Resource; Food and Drug Administration: Silver Spring, MD, USA, 2021.
- Amiteye, S. Basic Concepts and Methodologies of DNA Marker Systems in Plant Molecular Breeding. Heliyon 2021, 7, e08093. [Google Scholar] [CrossRef] [PubMed]
- Verma, M.; Patel, P.; Verma, M. Biomarkers in Prostate Cancer Epidemiology. Cancers 2011, 3, 3773–3798. [Google Scholar] [CrossRef]
- Pinu, F.R.; Goldansaz, S.A.; Jaine, J. Translational Metabolomics: Current Challenges and Future Opportunities. Metabolites 2019, 9, 108. [Google Scholar] [CrossRef]
- Strimbu, K.; Tavel, J.A. What Are Biomarkers? Curr. Opin. HIV AIDS 2010, 5, 463–466. [Google Scholar] [CrossRef]
- Slikker, W. Biomarkers and Their Impact on Precision Medicine. Exp. Biol. Med. 2018, 243, 211–212. [Google Scholar] [CrossRef]
- Koussiouris, J.; Looby, N.; Anderson, M.; Kulasingam, V.; Chandran, V. Metabolomics Studies in Psoriatic Disease: A Review. Metabolites 2021, 11, 375. [Google Scholar] [CrossRef]
- Jutley, G.S.; Young, S.P. Metabolomics to Identify Biomarkers and as a Predictive Tool in Inflammatory Diseases. Best. Pract. Res. Clin. Rheumatol. 2015, 29, 770–782. [Google Scholar] [CrossRef]
- Cui, L.; Lu, H.; Lee, Y.H. Challenges and Emergent Solutions for LC-MS/MS Based Untargeted Metabolomics in Diseases. Mass Spectrom. Rev. 2018, 37, 772–792. [Google Scholar] [CrossRef] [PubMed]
- Vuckovic, D. Improving Metabolome Coverage and Data Quality: Advancing Metabolomics and Lipidomics for Biomarker Discovery. Chem. Commun. 2018, 54, 6728–6749. [Google Scholar] [CrossRef] [PubMed]
- Monteiro, M.S.; Carvalho, M.; Bastos, M.L.; Guedes De Pinho, P. Metabolomics Analysis for Biomarker Discovery: Advances and Challenges. Curr. Med. Chem. 2013, 20, 257–271. [Google Scholar] [CrossRef]
- Xia, J.; Broadhurst, D.I.; Wilson, M.; Wishart, D.S. Translational Biomarker Discovery in Clinical Metabolomics: An Introductory Tutorial. Metabolomics 2013, 9, 280–299. [Google Scholar] [CrossRef]
- Grebe, S.K.; Singh, R.J. LC-MSMS in Clinical Lab—Where to from Here. Clin. Biochem. Rev. 2011, 32, 5–31. [Google Scholar]
- López-López, Á.; López-Gonzálvez, Á.; Barker-Tejeda, T.C.; Barbas, C. A Review of Validated Biomarkers Obtained through Metabolomics. Expert. Rev. Mol. Diagn. 2018, 18, 557–575. [Google Scholar] [CrossRef]
- Food and Drug Administration; Center for Drug Evaluation and Research; Center for Veterinary Medicine. Bioanalytical Method. Validation Guidance for Industry Biopharmaceutics Bioanalytical Method. Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations; Food and Drug Administration: Silver Spring, MD, USA, 2018.
- Hewitt, S.M.; Badve, S.S.; True, L.D. Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy. Clin. Cancer Res. 2012, 18, 1524–1530. [Google Scholar] [CrossRef]
- Zhang, R.; Sun, X.; Huang, Z.; Pan, Y.; Westbrook, A.; Li, S.; Bazzano, L.; Chen, W.; He, J.; Kelly, T.; et al. Examination of Serum Metabolome Altered by Cigarette Smoking Identifies Novel Metabolites Mediating Smoking-BMI Association. Obesity 2022, 30, 943–952. [Google Scholar] [CrossRef]
- Bar, N.; Korem, T.; Weissbrod, O.; Zeevi, D.; Rothschild, D.; Leviatan, S.; Kosower, N.; Lotan-Pompan, M.; Weinberger, A.; Le Roy, C.I.; et al. A Reference Map of Potential Determinants for the Human Serum Metabolome. Nature 2020, 588, 135–140. [Google Scholar] [CrossRef]
- Maitre, L.; Bustamante, M.; Hernández-Ferrer, C.; Thiel, D.; Lau, C.H.E.; Siskos, A.P.; Vives-Usano, M.; Ruiz-Arenas, C.; Pelegrí-Sisó, D.; Robinson, O.; et al. Multi-Omics Signatures of the Human Early Life Exposome. Nat. Commun. 2022, 13, 7024. [Google Scholar] [CrossRef]
- Yang, Q.J.; Zhao, J.R.; Hao, J.; Li, B.; Huo, Y.; Han, Y.L.; Wan, L.L.; Li, J.; Huang, J.; Lu, J.; et al. Serum and Urine Metabolomics Study Reveals a Distinct Diagnostic Model for Cancer Cachexia. J. Cachexia Sarcopenia Muscle 2018, 9, 71–85. [Google Scholar] [CrossRef]
- Han, L.; Zhao, L.; Zhou, Y.; Yang, C.; Xiong, T.; Lu, L.; Deng, Y.; Luo, W.; Chen, Y.; Qiu, Q.; et al. Altered Metabolome and Microbiome Features Provide Clues in Understanding Irritable Bowel Syndrome and Depression Comorbidity. ISME J. 2022, 16, 983–996. [Google Scholar] [CrossRef]
- Slade, E.; Irvin, M.R.; Xie, K.; Arnett, D.K.; Claas, S.A.; Kind, T.; Fardo, D.W.; Graf, G.A. Age and Sex Are Associated with the Plasma Lipidome: Findings from the GOLDN Study. Lipids Health Dis. 2021, 20, 30. [Google Scholar] [CrossRef]
- Andraos, S.; Lange, K.; Clifford, S.A.; Jones, B.; Thorstensen, E.B.; Wake, M.; Burgner, D.P.; Saffery, R.; O’Sullivan, J.M. Population Epidemiology and Concordance for Plasma Amino Acids and Precursors in 11–12-Year-Old Children and Their Parents. Sci. Rep. 2021, 11, 3619. [Google Scholar] [CrossRef]
- Vignoli, A.; Tenori, L.; Luchinat, C.; Saccenti, E. Age and Sex Effects on Plasma Metabolite Association Networks in Healthy Subjects. J. Proteome Res. 2018, 17, 97–107. [Google Scholar] [CrossRef]
- Tabassum, R.; Ruotsalainen, S.; Ottensmann, L.; Gerl, M.J.; Klose, C.; Tukiainen, T.; Pirinen, M.; Simons, K.; Widén, E.; Ripatti, S. Lipidome-and Genome-Wide Study to Understand Sex Differences in Circulatory Lipids. J. Am. Heart Assoc. 2022, 11, e027103. [Google Scholar] [CrossRef]
- Liu, W.; Zhang, L.; Shi, X.; Shen, G.; Feng, J. Cross-Comparative Metabolomics Reveal Sex-Age Specific Metabolic Fingerprints and Metabolic Interactions in Acute Myocardial Infarction. Free Radic. Biol. Med. 2022, 183, 25–34. [Google Scholar] [CrossRef]
- Garwolińska, D.; Kot-Wasik, A.; Hewelt-Belka, W. Pre-Analytical Aspects in Metabolomics of Human Biofluids—Sample Collection, Handling, Transport, and Storage. Mol. Omics 2022, 19, 95–104. [Google Scholar] [CrossRef]
- Kirwan, J.A.; Brennan, L.; Broadhurst, D.; Fiehn, O.; Cascante, M.; Dunn, W.B.; Schmidt, M.A.; Velagapudi, V. Preanalytical Processing and Biobanking Procedures of Biological Samples for Metabolomics Research: A White Paper, Community Perspective (for “Precision Medicine and Pharmacometabolomics Task Group”—The Metabolomics Society Initiative). Clin. Chem. 2018, 64, 1158–1182. [Google Scholar] [CrossRef]
- Khadka, M.; Todor, A.; Maner-Smith, K.M.; Colucci, J.K.; Tran, V.; Gau, D.A.; Anderson, E.J.; Natrajan, M.S.; Rouphae, N.; Mulligan, M.J.; et al. The Effect of Anticoagulants, Temperature, and Time on the Human Plasma Metabolome and Lipidome from Healthy Donors as Determined by Liquid Chromatography-Mass Spectrometry. Biomolecules 2019, 9, 200. [Google Scholar] [CrossRef]
- Dallmann, R.; Viola, A.U.; Tarokh, L.; Cajochen, C.; Brown, S.A. The Human Circadian Metabolome. Proc. Natl. Acad. Sci. USA 2012, 109, 2625–2629. [Google Scholar] [CrossRef]
- Ang, J.E.; Revell, V.; Mann, A.; Mäntele, S.; Otway, D.T.; Johnston, J.D.; Thumser, A.E.; Skene, D.J.; Raynaud, F. Identification of Human Plasma Metabolites Exhibiting Time-of-Day Variation Using an Untargeted Liquid Chromatographymass Spectrometry Metabolomic Approach. Chronobiol. Int. 2012, 29, 868–881. [Google Scholar] [CrossRef]
- Abbondante, S.; Eckel-Mahan, K.L.; Ceglia, N.J.; Baldi, P.; Sassone-Corsi, P. Comparative Circadian Metabolomics Reveal Differential Effects of Nutritional Challenge in the Serum and Liver. J. Biol. Chem. 2016, 291, 2812–2828. [Google Scholar] [CrossRef]
- Shrestha, A.; Müllner, E.; Poutanen, K.; Mykkänen, H.; Moazzami, A.A. Metabolic Changes in Serum Metabolome in Response to a Meal. Eur. J. Nutr. 2017, 56, 671–681. [Google Scholar] [CrossRef]
- Malagelada, C.; Pribic, T.; Ciccantelli, B.; Cañellas, N.; Gomez, J.; Amigo, N.; Accarino, A.; Correig, X.; Azpiroz, F. Metabolomic Signature of the Postprandial Experience. Neurogastroenterol. Motil. 2018, 30, e13447. [Google Scholar] [CrossRef]
- McClain, K.M.; Moore, S.C.; Sampson, J.N.; Henderson, T.R.; Gebauer, S.K.; Newman, J.W.; Ross, S.; Pedersen, T.L.; Baer, D.J.; Zanetti, K.A. Preanalytical Sample Handling Conditions and Their Effects on the Human Serum Metabolome in Epidemiologic Studies. Am. J. Epidemiol. 2021, 190, 459–467. [Google Scholar] [CrossRef]
- Teahan, O.; Gamble, S.; Holmes, E.; Waxman, J.; Nicholson, J.K.; Bevan, C.; Keun, H.C. Impact of Analytical Bias in Metabonomic Studies of Human Blood Serum and Plasma. Anal. Chem. 2006, 78, 4307–4318. [Google Scholar] [CrossRef]
- Searfoss, R.; Shah, P.; Ofori-Mensa, K.; Bussberg, V.; Tolstikov, V.; Greenwood, B.; Li, H.; Richardson, K.; Miller, G.M.; DeCicco, C.; et al. Impact of Hemolysis on Multi-OMIC Pancreatic Biomarker Discovery to Derisk Biomarker Development in Precision Medicine Studies. Sci. Rep. 2022, 12, 1186. [Google Scholar] [CrossRef]
- Lippi, G.; Blanckaert, N.; Bonini, P.; Green, S.; Kitchen, S.; Palicka, V.; Vassault, A.J.; Plebani, M. Haemolysis: An Overview of the Leading Cause of Unsuitable Specimens in Clinical Laboratories. Clin. Chem. Lab. Med. 2008, 46, 764–772. [Google Scholar] [CrossRef]
- Yin, P.; Peter, A.; Franken, H.; Zhao, X.; Neukamm, S.S.; Rosenbaum, L.; Lucio, M.; Zell, A.; Häring, H.U.; Xu, G.; et al. Preanalytical Aspects and Sample Quality Assessment in Metabolomics Studies of Human Blood. Clin. Chem. 2013, 59, 833–845. [Google Scholar] [CrossRef]
- López-Bascón, M.A.; Priego-Capote, F.; Peralbo-Molina, A.; Calderón-Santiago, M.; Luque De Castro, M.D. Influence of the Collection Tube on Metabolomic Changes in Serum and Plasma. Talanta 2016, 150, 681–689. [Google Scholar] [CrossRef]
- Bowen, R.A.R.; Hortin, G.L.; Csako, G.; Otañez, O.H.; Remaley, A.T. Impact of Blood Collection Devices on Clinical Chemistry Assays. Clin. Biochem. 2010, 43, 4–25. [Google Scholar] [CrossRef]
- Valo, E.; Colombo, M.; Sandholm, N.; McGurnaghan, S.J.; Blackbourn, L.A.K.; Dunger, D.B.; McKeigue, P.M.; Forsblom, C.; Groop, P.H.; Colhoun, H.M.; et al. Effect of Serum Sample Storage Temperature on Metabolomic and Proteomic Biomarkers. Sci. Rep. 2022, 12, 4571. [Google Scholar] [CrossRef]
- Smith, L.; Villaret-Cazadamont, J.; Claus, S.P.; Canlet, C.; Guillou, H.; Cabaton, N.J.; Ellero-Simatos, S. Important Considerations for Sample Collection in Metabolomics Studies with a Special Focus on Applications to Liver Functions. Metabolites 2020, 10, 104. [Google Scholar] [CrossRef]
- Qiu, S.; Cai, Y.; Yao, H.; Lin, C.; Xie, Y.; Tang, S.; Zhang, A. Small Molecule Metabolites: Discovery of Biomarkers and Therapeutic Targets. Signal Transduct. Target. Ther. 2023, 8, 132. [Google Scholar]
- Tounta, V.; Liu, Y.; Cheyne, A.; Larrouy-Maumus, G. Metabolomics in Infectious Diseases and Drug Discovery. Mol. Omics 2021, 17, 376–393. [Google Scholar] [CrossRef]
- Committee for Medicinal Products for Human Use. ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis Step5; European Medicines Agency: Amsterdam, The Netherlands, 2022.
- Kaza, M.; Karaźniewicz-Łada, M.; Kosicka, K.; Siemiątkowska, A.; Rudzki, P.J. Bioanalytical Method Validation: New FDA Guidance vs. EMA Guideline. Better or Worse? J. Pharm. Biomed. Anal. 2019, 165, 381–385. [Google Scholar] [CrossRef]
- Gil, A.; Siegel, D.; Permentier, H.; Reijngoud, D.J.; Dekker, F.; Bischoff, R. Stability of Energy Metabolites-An Often Overlooked Issue in Metabolomics Studies: A Review. Electrophoresis 2015, 36, 2156–2169. [Google Scholar] [CrossRef]
- Wishart, D.S.; Guo, A.C.; Oler, E.; Wang, F.; Anjum, A.; Peters, H.; Dizon, R.; Sayeeda, Z.; Tian, S.; Lee, B.L.; et al. HMDB 5.0: The Human Metabolome Database for 2022. Nucleic Acids Res 2022, 50, D622–D631. [Google Scholar] [CrossRef]
- Rappaport, S.M.; Barupal, D.K.; Wishart, D.; Vineis, P.; Scalbert, A. The Blood Exposome and Its Role in Discovering Causes of Disease. Environ. Health Perspect. 2014, 122, 769–774. [Google Scholar] [CrossRef]
- Psychogios, N.; Hau, D.D.; Peng, J.; Guo, A.C.; Mandal, R.; Bouatra, S.; Sinelnikov, I.; Krishnamurthy, R.; Eisner, R.; Gautam, B.; et al. The Human Serum Metabolome. PLoS ONE 2011, 6, e16957. [Google Scholar] [CrossRef]
- Song, J.W.; Lam, S.M.; Fan, X.; Cao, W.J.; Wang, S.Y.; Tian, H.; Chua, G.H.; Zhang, C.; Meng, F.P.; Xu, Z.; et al. Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. Cell Metab. 2020, 32, 188–202.e5. [Google Scholar] [CrossRef]
- Choksi, H.; Li, S.; Looby, N.; Kotlyar, M.; Jurisica, I.; Kulasingam, V.; Chandran, V. Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis. Int. J. Mol. Sci. 2023, 24, 15299. [Google Scholar] [CrossRef]
- Luo, P.; Yin, P.; Hua, R.; Tan, Y.; Li, Z.; Qiu, G.; Yin, Z.; Xie, X.; Wang, X.; Chen, W.; et al. A Large-scale, Multicenter Serum Metabolite Biomarker Identification Study for the Early Detection of Hepatocellular Carcinoma. Hepatology 2018, 67, 662–675. [Google Scholar] [CrossRef]
- Chen, F.; Dai, X.; Zhou, C.-C.; Li, K.; Zhang, Y.; Lou, X.-Y.; Zhu, Y.-M.; Sun, Y.-L.; Peng, B.-X.; Cui, W. Integrated Analysis of the Faecal Metagenome and Serum Metabolome Reveals the Role of Gut Microbiome-Associated Metabolites in the Detection of Colorectal Cancer and Adenoma. Gut 2022, 71, 1315–1325. [Google Scholar] [CrossRef]
- Skubitz, A.P.N.; Boylan, K.L.M.; Geschwind, K.; Cao, Q.; Starr, T.K.; Geller, M.A.; Celestino, J.; Bast, R.C.; Lu, K.H.; Koopmeiners, J.S. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. Cancer Prev. Res. 2019, 12, 171–183. [Google Scholar] [CrossRef]
- Alseekh, S.; Aharoni, A.; Brotman, Y.; Contrepois, K.; D’Auria, J.; Ewald, J.; Ewald, J.C.; Fraser, P.D.; Giavalisco, P.; Hall, R.D.; et al. Mass Spectrometry-Based Metabolomics: A Guide for Annotation, Quantification and Best Reporting Practices. Nat. Methods 2021, 18, 747–756. [Google Scholar] [CrossRef]
- Fiandaca, M.S.; Mapstone, M.; Mahmoodi, A.; Gross, T.; Macciardi, F.; Cheema, A.K.; Merchant-Borna, K.; Bazarian, J.; Federoff, H.J. Plasma Metabolomic Biomarkers Accurately Classify Acute Mild Traumatic Brain Injury from Controls. PLoS ONE 2018, 13, e0195318. [Google Scholar] [CrossRef]
- Blau, N.; Shen, N.; Carducci, C. Molecular Genetics and Diagnosis of Phenylketonuria: State of the Art. Expert. Rev. Mol. Diagn. 2014, 14, 655–671. [Google Scholar] [CrossRef]
- Matsuda, R.; Bi, C.; Anguizola, J.; Sobansky, M.; Rodriquez, E.; Vargas Badilla, J.; Zheng, X.; Hage, B.; Hage, D.S. Studies of Metabolite-Protein Interactions: A Review. J. Chromatogr. 2014, 966, 48–58. [Google Scholar] [CrossRef]
- Luzarowski, M.; Vicente, R.; Kiselev, A.; Wagner, M.; Schlossarek, D.; Erban, A.; de Souza, L.P.; Childs, D.; Wojciechowska, I.; Luzarowska, U.; et al. Global Mapping of Protein–Metabolite Interactions in Saccharomyces Cerevisiae Reveals That Ser-Leu Dipeptide Regulates Phosphoglycerate Kinase Activity. Commun. Biol. 2021, 4, 181. [Google Scholar] [CrossRef]
- Hanley, M.J.; Cancalon, P.; Widmer, W.W.; Greenblatt, D.J. The Effect of Grapefruit Juice on Drug Disposition. Expert. Opin. Drug Metab. Toxicol. 2011, 7, 267–286. [Google Scholar] [CrossRef]
- Shulpekova, Y.; Zharkova, M.; Tkachenko, P.; Tikhonov, I.; Stepanov, A.; Synitsyna, A.; Izotov, A.; Butkova, T.; Shulpekova, N.; Lapina, N.; et al. The Role of Bile Acids in the Human Body and in the Development of Diseases. Molecules 2022, 27, 3401. [Google Scholar] [CrossRef]
- Budelier, M.M.; Hubbard, J.A. The Regulatory Landscape of Laboratory Developed Tests: Past, Present, and a Perspective on the Future. J. Mass Spectrom. Adv. Clin. Lab. 2023, 28, 67–69. [Google Scholar] [CrossRef]
- Lichtenberg, S.; Trifonova, O.P.; Maslov, D.L.; Balashova, E.E.; Lokhov, P.G. Metabolomic Laboratory-Developed Tests: Current Status and Perspectives. Metabolites 2021, 11, 423. [Google Scholar] [CrossRef]
- Health Canada. Guidance Document—Labelling of In Vitro Diagnostic Devices; Health Canada: Toronto, ON, Canada, 2016. [Google Scholar]
- Food and Drug Administration. CFR—Code of Federal Regulations Title 21 Chapter I-Food and Drug Administration Department of Health and Human Services Subchapter H—Medical Devices; Food and Drug Administration: Silver Spring, MD, USA, 2024.
- Food and Drug Administration. Medical Devices; Quality System Regulation Amendments 2024. Available online: https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments (accessed on 11 February 2024).
- Biocrates AbsoluteIDQ® P400 HR Kit. Available online: https://biocrates.com/absoluteidq-p400-hr-kit/ (accessed on 21 March 2024).
- The Metabolomics Innovation Center Clinical Biomarker Assay 2.0 (TMIC MEGA). Available online: https://www.metabolomix.ca/lcms-kits (accessed on 21 March 2024).
- Med-Life Discoveries LP GTA-446 Tandem-MS Test Kit. Available online: https://med-life.ca/gta446-test-kit (accessed on 21 March 2024).
- Hata, T.; Takemasa, I.; Takahashi, H.; Haraguchi, N.; Nishimura, J.; Hata, T.; Mizushima, T.; Doki, Y.; Mori, M. Downregulation of Serum Metabolite GTA-446 as a Novel Potential Marker for Early Detection of Colorectal Cancer. Br. J. Cancer 2017, 117, 227–232. [Google Scholar] [CrossRef]
- Deng, L.; Chang, D.; Foshaug, R.R.; Eisner, R.; Tso, V.K.; Wishart, D.S.; Fedorak, R.N. Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. Metabolites 2017, 7, 32. [Google Scholar] [CrossRef]
- OwlMetabolomics PANEL OWLiver. Available online: https://owlmetabolomics.com/diagnostic-tests/ (accessed on 21 March 2024).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, S.; Looby, N.; Chandran, V.; Kulasingam, V. Challenges in the Metabolomics-Based Biomarker Validation Pipeline. Metabolites 2024, 14, 200. https://doi.org/10.3390/metabo14040200
Li S, Looby N, Chandran V, Kulasingam V. Challenges in the Metabolomics-Based Biomarker Validation Pipeline. Metabolites. 2024; 14(4):200. https://doi.org/10.3390/metabo14040200
Chicago/Turabian StyleLi, Shenghan, Nikita Looby, Vinod Chandran, and Vathany Kulasingam. 2024. "Challenges in the Metabolomics-Based Biomarker Validation Pipeline" Metabolites 14, no. 4: 200. https://doi.org/10.3390/metabo14040200